The DOI matches its Crossref record; 196 of the 196 references it cites were found in a registry or an index.
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Open accessAbstract
Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for treatment of the latter by developing a wide variety of inhibitors. HDAC inhibitors interfere with HDAC activity and regulate biological events, such as cell cycle, differentiation and apoptosis in cancer cells. As a result, HDAC inhibitor-based therapies have gained much attention for cancer treatment. To date, the FDA has approved three HDAC inhibitors for cutaneous/peripheral T-cell lymphoma and many more HDAC inhibitors are in different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. In the intensifying efforts to discover new, hopefully more therapeutically efficacious HDAC inhibitors, molecular modeling-based rational drug design has played an important role in identifying potential inhibitors that vary in molecular structures and properties. In this review, we summarize four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Roth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
Sirtuins in mammals: insights into their biological function
Michan, S., & Sinclair, D. (2007) · Biochemical Journal · doi:10.1042/bj20070140 · Cited by 1,718
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Inhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
The structure of DNA in the nucleosome core
Richmond, T. J., & Davey, C. A. (2003) · Nature · doi:10.1038/nature01595 · Cited by 1,286
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 1×
“of the active site, whereas the metal binding moiety resides in the interior of the protein and form complexes with the metal ion [34,154–156].”
BackgroundSaito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4223 · Cited by 680
Khorasanizadeh, S. (2004) · Cell · doi:10.1016/s0092-8674(04)00044-3 · Cited by 674
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
Discovery and development of SAHA as an anticancer agent
Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210204 · Cited by 626
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
(2011) · PubMed Central · Cited by 560
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Prospects: Histone deacetylase inhibitors
Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 479
(2003) · PubMed · Cited by 465
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · cited 1×
“of the active site, whereas the metal binding moiety resides in the interior of the protein and form complexes with the metal ion [34,154–156].”
BackgroundTaori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication
Yang, X.-J., & Grégoire, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.2873-2884.2005 · Cited by 419
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Lax, S. F. (2004) · Virchows Archiv · doi:10.1007/s00428-003-0947-3 · Cited by 378
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 376
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Lee, J.-H., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008522107 · Cited by 363
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Nonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S.-W. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 300
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 299
Mahalingam, D., Mita, M., Sarantopoulos, J., Wood, L., Amaravadi, R. K., Davis, L. E., Mita, A. C., Curiel, T. J., Espitia, C. M., Nawrocki, S. T., et al. (2014) · Autophagy · doi:10.4161/auto.29231 · Cited by 285
Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P., Gallagher, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1350 · Cited by 263
Druesne, N. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh123 · Cited by 254
Aoyama, M., Kotani, J., & Usami, M. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.006 · Cited by 245
Rambaldi, A., Dellacasa, C. M., Finazzi, G., Carobbio, A., Ferrari, M. L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M. C., Di Tollo, S., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08266.x · Cited by 242
Duan, H., Heckman, C. A., & Boxer, L. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1608-1619.2005 · Cited by 242
Dietary Sulforaphane, a Histone Deacetylase Inhibitor for Cancer Prevention
Ho, E., Clarke, J. D., & Dashwood, R. H. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.113332 · Cited by 241
Richon, V. M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603463 · Cited by 238
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 233
The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations
Bonda, D. J., Lee, H.-G., Camins, A., Pallàs, M., Casadesus, G., Smith, M. A., & Zhu, X. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70013-8 · Cited by 221
Belinostat: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0275-8 · Cited by 216
Kwon, S. H., Ahn, S. H., Kim, Y. K., Bae, G.-U., Yoon, J. W., Hong, S., Lee, H. Y., Lee, Y.-W., Lee, H.-W., & Han, J.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106699200 · Cited by 215
Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 212
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70265-0 · Cited by 196
Witta, S. E., Jotte, R. M., Konduri, K., Neubauer, M. A., Spira, A. I., Ruxer, R. L., Varella-Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 196
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K., & Johnstone, R. W. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.9 · Cited by 192
Zhang, X. D., Gillespie, S. K., Borrow, J. M., & Hersey, P. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.425.3.4 · Cited by 190
Giaccone, G., Rajan, A., Berman, A., Kelly, R. J., Szabo, E., Lopez-Chavez, A., Trepel, J., Lee, M.-J., Cao, L., Espinoza-Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4467 · Cited by 189
The emerging role of class II histone deacetylases
Fischle, W., Kiermer, V., Dequiedt, F., & Verdin, E. (2001) · Biochemistry and Cell Biology · doi:10.1139/bcb-79-3-337 · Cited by 181
Marek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
Histone modifications and chromatin dynamics: a focus on filamentous fungi
Brosch, G., Loidl, P., & Graessle, S. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2007.00100.x · Cited by 173
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171
Venturelli, S., Berger, A., Böcker, A., Busch, C., Weiland, T., Noor, S., Leischner, C., Schleicher, S., Mayer, M., Weiss, T. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073097 · Cited by 169
Sirtuin Inhibitors as Anticancer Agents
Hu, J., Jing, H., & Lin, H. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.44 · Cited by 169
Пили, Р., Salumbides, B. C., Zhao, M., Altiok, S., Qian, D. Z., Zwiebel, J. A., Carducci, M. A., & Rudek, M. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.527 · Cited by 160
MacKay, H. J., Hirte, H. W., Colgan, T. J., Covens, A., MacAlpine, K., Grenci, P., Wang, L. E., Mason, J., Pham, P.-A., Tsao, M., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.047 · Cited by 160
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
NAD+, Sirtuins, and Cardiovascular Disease
Borradaile, N. M., & Pickering, J. G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787185742 · Cited by 158
Millward, M., Price, T. J., Townsend, A. R., Sweeney, C. J., Spencer, A. G., Sukumaran, S., Longenecker, A. M., Lee, L., Lay, A., Sharma, G. D., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9766-6 · Cited by 156
Trifluoromethyl ketones as inhibitors of histone deacetylase
Frey, R. R., Wada, C. K., Garland, R. B., Curtin, M. L., Michaelides, M. R., Li, J., Pease, L. J., Glaser, K. B., Marcotte, P. A., Bouska, J. J., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00754-0 · Cited by 149
Bishton, M. J., Harrison, S. J., Martin, B. P., McLaughlin, N. M., James, C., Josefsson, E. C., Henley, K. J., Kile, B. T., Prince, H. M., & Johnstone, R. W. (2011) · Blood · doi:10.1182/blood-2010-11-318055 · Cited by 147
Nian, H., Delage, B., Pinto, J. T., & Dashwood, R. H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn165 · Cited by 139
Chronic Oral Administration of CI-994: A Phase I Study
Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136
Finazzi, G., Vannucchi, A. M., Martinelli, V., Ruggeri, M., Nobile, F., Specchia, G., Pogliani, E. M., Olimpieri, O. M., Fioritoni, G., Musolino, C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12332 · Cited by 130
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 126
Furlan, A., Monzani, V., Reznikov, L. L., Leoni, F., Fossati, G., Modena, D., Mascagni, P., & Dinarello, C. A. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00020 · Cited by 120
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma
Buglio, D., Khaskhely, N. M., Voo, K. S., Martínez-Valdez, H., Liu, Y., & Younes, A. (2011) · Blood · doi:10.1182/blood-2010-08-303701 · Cited by 119
Siu, L. L., Пили, Р., Durán, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 119
Blum, K. A., Advani, A., FERNANDEZ, L. A. V., van der Jagt, R., Brandwein, J. M., Kambhampati, S., Kassis, J., Davis, M. E., Bonfils, C., Dubay, M., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07881.x · Cited by 114
Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer
Peng, L., & Seto, E. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_3 · Cited by 113
Su, J. M. F., Li, X., Thompson, P., Ou, C., Ingle, A. M., Russell, H. V., Lau, C. C., Adamson, P. C., & Blaney, S. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0738 · Cited by 113
Chen, P. C., Patil, V., Guerrant, W., Green, P., & Oyelere, A. K. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.050 · Cited by 112
Neelarapu, R., Holzle, D. L., Velaparthi, S., Bai, H., Brunsteiner, M., Blond, S. Y., & Petukhov, P. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2001025 · Cited by 104
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602047 · Cited by 104
Dizon, D. S., Blessing, J. A., Penson, R. T., Drake, R. D., Walker, J. L., Johnston, C. M., DiSilvestro, P., & Fader, A. N. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.019 · Cited by 102
Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N., & Rambaldi, A. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0793-8 · Cited by 101
Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors
Olson, D. E., Wagner, F. F., Kaya, T., Gale, J. P., Aidoud, N., Davoine, E. L., Lazzaro, F., Weïwer, M., Zhang, Y., & Holson, E. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400390r · Cited by 98
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Thomas, A., Rajan, A., Szabo, E. M., Tomita, Y., Carter, C. A., Scepura, B., López-Chávez, A., Lee, M.-J., Redon, C. E., Frosch, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0968 · Cited by 94
A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma
Mohammed, T. A., Holen, K. D., Jaskula‐Sztul, R., Mulkerin, D. L., Lubner, S. J., Schelman, W. R., Eickhoff, J. C., Chen, H., & LoConte, N. K. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0031 · Cited by 92
Pontiki, E. A., & Hadjipavlou‐Litina, D. (2010) · Medicinal Research Reviews · doi:10.1002/med.20200 · Cited by 91
On the inhibition of histone deacetylase 8
Estiu, G. L., West, N. H., Mazitschek, R., Greenberg, E. F., Bradner, J. E., & Wiest, O. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.080 · Cited by 90
Chu, B. F., Karpenko, M., Liu, Z., Aimiuwu, J., Villalona-Calero, M. A., Chan, K. K. L., Grever, M. R., & Otterson, G. A. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1986-8 · Cited by 90
Mandl–Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F. S., Schmidmaier, R., & Baumann, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08124.x · Cited by 87
Dizon, D. S., Damstrup, L., Finkler, N. J., Lassen, U., Celano, P., Glasspool, R. M., Crowley, E. M., Lichenstein, H. S., Knoblach, P., & Penson, R. T. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31825736fd · Cited by 87
Acetylation/Deacetylation Modulates the Stability of DNA Replication Licensing Factor Cdt1
Glozak, M. A., & Seto, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809394200 · Cited by 86
Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85
Schepper, S. D., Bruwiere, H., Verhulst, T., Steller, U., Andries, L. J., Wouters, W., Janicot, M., Arts, J., & Heusden, J. V. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042903 · Cited by 84
Lopez, G., Liu, J., Ren, W., Wei, W., Wang, S., Lahat, G., Zhu, Q.-S., Bornmann, W. G., McConkey, D. J., Pollock, R. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2714 · Cited by 82
Mascarenhas, J. O., Lü, M., Li, T., Petersen, B. E., Hochman, T., Najfeld, V., Goldberg, J. D., & Hoffman, R. (2013) · British Journal of Haematology · doi:10.1111/bjh.12220 · Cited by 78
Selvaraju, K., Renu, S., Krishnamoorthy, V., & Ravikumar, V. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.01.002 · Cited by 77
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
Quintás‐Cardama, A., Kantarjian, H. M., Estrov, Z. E., et al. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.003 · Cited by 75
The Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 1–11
Madsen, A. S., Kristensen, H. M. E., Lanz, G., & Olsen, C. A. (2013) · ChemMedChem · doi:10.1002/cmdc.201300433 · Cited by 74
Kirschbaum, M. H., Foon, K. A., Frankel, P. H., Ruel, C., Pulone, B., Tuscano, J. M., & Newman, E. M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.877134 · Cited by 74
Thioredoxin in cancer—Role of histone deacetylase inhibitors
Marks, P. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.09.005 · Cited by 72
Razak, A. R. A., Hotte, S. J., Siu, L. L., Chen, E. X., Hirte, H. W., Powers, J., Walsh, W. R., Stayner, L.-A., Laughlin, A., Novotny‐Diermayr, V., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.13 · Cited by 68
Thangapandian, S., John, S., Sakkiah, S., & Woo, L. K. (2010) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2010.07.007 · Cited by 68
Rajak, H., Singh, A. J., Raghuwanshi, K. K., et al. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990191 · Cited by 68
Ma, B. B. Y., Sung, F. L., Tao, Q., Poon, F. F., Lui, V. W. Y., Yeo, W., Chan, S. L., & Chan, A. T. �. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9219-7 · Cited by 66
Pohlman, B. L., Advani, R. H., Duvic, M. A., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Ben‐Yehuda, D., Beylot-Barry, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.920.920 · Cited by 66
Anticancer Agents Targeted to Sirtuins
Kozako, T., Suzuki, T., Yoshimitsu, M., Arima, N., Honda, S., & Soeda, S. (2014) · Molecules · doi:10.3390/molecules191220295 · Cited by 65
Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Amiri‐Kordestani, L., Luchenko, V. L., Peer, C. J., Ghafourian, K., Reynolds, J. C., Draper, D., Frye, R., Woo, S., Venzon, D. J., Wright, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0095 · Cited by 65
Jose, B., Oniki, Y., Kato, T., Nishino, N., Sumida, Y., & Yoshida, M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.016 · Cited by 65
Cashen, A. F., Juckett, M. B., Jumonville, A. J., Litzow, M. R., Flynn, P. J., Eckardt, J. R., LaPlant, B. R., Laumann, K. M., Erlichman, C., & DiPersio, J. F. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1240-1 · Cited by 63
Wilson, P. M., El-Khoueiry, A. B., Iqbal, S., Fazzone, W., LaBonte, M. J., Groshen, S. G., Yang, D., Danenberg, K. D., Cole, S., Kornacki, M., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1236-x · Cited by 59
Du, L., Risinger, A. L., King, J. B., Powell, D. R., & Cichewicz, R. H. (2014) · Journal of Natural Products · doi:10.1021/np500387h · Cited by 59
Silva, G. P. D. L., Cardoso, B. A., Belo, H., & Almeida, A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053766 · Cited by 58
Phosphorus-Based SAHA Analogues as Histone Deacetylase Inhibitors
Kapustin, G. V., Fejér, G., Gronlund, J. L., McCafferty, D. G., Seto, E., & Etzkorn, F. A. (2003) · Organic Letters · doi:10.1021/ol035056n · Cited by 57
Brunetto, A. T., Ang, J. E., Lal, R., Olmos, D., Molife, L. R., Kristeleit, R. S., Parker, A., Casamayor, I., Olaleye, M., Mais, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0735 · Cited by 56
Wheler, J. J., Jankú, F., Falchook, G. S., Jackson, T. L., Fu, S., Naing, A., Tsimberidou, A. M., Moulder, S., Hong, D. S., Yang, H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2384-1 · Cited by 56
Wang, G., He, J., Zhao, J., Yun, W., Xie, C., Taub, J. W., Azmi, A. S., Mohammad, R. M., Dong, Y., Kong, W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052095 · Cited by 55
Self-citationPetrella, A., D’Acunto, C. W., Rodriquez, M., Festa, M., Tosco, A., Bruno, I., Terracciano, S., Taddei, M., Paloma, L. G., & Parente, L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.023 · Cited by 55
Jones, S. F., Infante, J. R., Spigel, D. R., Peacock, N. W., Thompson, D. S., Greco, F. A., McCulloch, W. F., & Burris, H. A. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.675382 · Cited by 54
Park, H., Kim, S., Kim, Y. E., & Lim, S. (2010) · ChemMedChem · doi:10.1002/cmdc.200900500 · Cited by 52
Zorzi, A. P., Bernstein, M. L., Samson, Y., Wall, D. A., Desai, S. J., Nicksy, D., Wainman, N., Eisenhauer, E. A., & Baruchel, S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24694 · Cited by 50
Canela, M., Pérez‐Pérez, M., Noppen, S., Sáez-Calvo, G., Díaz, J. F., Camarasa, M., Liekens, S., & Priego, E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401939g · Cited by 49
Gu, W., Nusinzon, I., Smith, R. D., Horvath, C. M., & Silverman, R. B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.047 · Cited by 49
Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes
Kalyaanamoorthy, S., & Chen, Y. P. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.08.009 · Cited by 48
Zheng, S., Zhong, Q., Jiang, Q., Mottamal, M., Zhang, Q., Zhu, N., Burow, M. E., Worthylake, R. A., & Wang, G. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300322n · Cited by 48
Self-citationŠvajger, U., Brus, B., Turk, S., Sova, M., Hodnik, V., Anderluh, G., & Gobec, S. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.019 · Cited by 48
Robertson, F. M., Chu, K., Boley, K. M., Ye, Z., Liu, H., Wright, M. C., Moraes, R., Zhang, X., Green, T. L., Barsky, S. H., et al. (2013) · PubMed · Cited by 47
Savickienė, J., Treigytė, G., Valiulienė, G., Stirblytė, I., & Navakauskienė, R. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000122 · Cited by 47
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., & Yamamoto, N. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9666-9 · Cited by 46
Fakih, M., Groman, A. E., McMahon, J., Wilding, G. E., & Muindi, J. R. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1762-1 · Cited by 46
Doi, T., Hamaguchi, T., Shirao, K., Chin, K., Hatake, K., Noguchi, K., Otsuki, T., Mehta, A., & Ohtsu, A. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0348-6 · Cited by 46
Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors
Schlimme, S., Hauser, A., Carafa, V., Heinke, R., Kannan, S., Stolfa, D. A., Cellamare, S., Carotti, A., Altucci, L., Jung, M., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201100007 · Cited by 45
Syntheses and Biological Activity of Amamistatin B and Analogs
Fennell, K. A., Möllmann, U., & Miller, M. J. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo7020532 · Cited by 45
Hassig, C. A., Symons, K. T., Guo, X., Nguyen, P.-M., Annable, T., Wash, P. L., Payne, J. E., Jenkins, D. A., Bonnefous, C., Trotter, C., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2347 · Cited by 45
Oki, Y., Younes, A., Copeland, A. R. M., Hagemeister, F. B., Fayad, L., McLaughlin, P. J., Shah, J. J., Fowler, N. H., Romaguera, J. E., Kwak, L. W., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12326 · Cited by 44
Syntheses of Amamistatin Fragments and Determination of Their HDAC and Antitumor Activity
Fennell, K. A., & Miller, M. J. (2007) · Organic Letters · doi:10.1021/ol070382e · Cited by 43
Fakih, M., Fetterly, G. J., Egorin, M. J., Muindi, J. R., Espinoza‐Delgado, I., Zwiebel, J. A., Litwin, A. M., Holleran, J. L., Wang, K., & Diasio, R. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0547 · Cited by 43
Morita, S., Oizumi, S., Minami, H., Kitagawa, K., Komatsu, Y., Fujiwara, Y., Inada, M., Yuki, S., Kiyota, N., Mitsuma, A., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9751-0 · Cited by 42
Iwahashi, S., Utsunomiya, T., Imura, S., Morine, Y., Ikemoto, T., Arakawa, Y., Saito, Y., Ishikawa, D., & Shimada, M. (2014) · PubMed · Cited by 41
Villadsen, J. S., Stephansen, H. M., Maolanon, A. R., Harris, P., & Olsen, C. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008449 · Cited by 41
Lee, C., Choi, E., Cho, M., Lee, B., Oh, S. J., Park, S.-K., Lee, K., Kim, H. M., & Han, G. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.045 · Cited by 41
Micco, S. D., Terracciano, S., Bruno, I., Rodriquez, M., Riccio, R., Taddei, M., & Bifulco, G. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.003 · Cited by 41
Lian, Z., Xu, Y., Wang, X., Gong, J., & Liu, Z. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2010.12.035 · Cited by 41
Salvador, L. A., Park, H., Al‐Awadhi, F. H., Liu, Y., Kim, B., Zeller, S. L., Chen, Q.-Y., Hong, J., & Luesch, H. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500170r · Cited by 40
Sælen, M. G., Ree, A. H., Kristian, A., Fleten, K. G., Furre, T., Hektoen, H. H., & Flatmark, K. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-165 · Cited by 39
Sarfstein, R., Bruchim, I., Fishman, A., & Werner, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024468 · Cited by 39
Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors
Tashima, T., Murata, H., & Kodama, H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.001 · Cited by 38
Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial
Shi, W., Lawrence, Y. R., Choy, H., Werner‐Wasik, M., Andrews, D. W., Evans, J. J., Judy, K. D., Farrell, C. J., Moshel, Y. A., Berger, A. C., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1433-2 · Cited by 37
Sodji, Q. H., Patil, V., Kornacki, J. R., Mrksich, M., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401225q · Cited by 36
Bermúdez-Lugo, J. A., Pérez-González, O. A., Rosales‐Hernández, M. C., Ilizaliturri‐Flores, I., Trujillo-Ferrara, J. G., & Correa‐Basurto, J. (2011) · Journal of Molecular Modeling · doi:10.1007/s00894-011-1240-z · Cited by 35
Fouliard, S., Robert, R., Jacquet-Bescond, A., du Rieu, Q. C., Balasubramanian, S., Loury, D. J., Loriot, Y., Hollebecque, A., Kloos, I., Soria, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.009 · Cited by 34
Amaru, A., Pedrini, O., Finazzi, G., Leoni, F., Mascagni, P., Introna, M., Rambaldi, A., & Golay, J. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.10.013 · Cited by 34
Choi, E., Lee, C., Park, J. E., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.079 · Cited by 34
Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
Baud, M. G. J., Leiser, T., Petrucci, V., Gunaratnam, M., Neidle, S., Meyer‐Almes, F., & Fuchter, M. J. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.11 · Cited by 32
A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers
Bauman, J. E., Shaheen, M., Verschraegen, C. F., Belinsky, S. A., Fekrazad, M. H., Lee, F.-C., Rabinowitz, I., Ravindranathan, M., & Jones, D. V. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.03.001 · Cited by 32
Molecular Modeling Study on Tunnel Behavior in Different Histone Deacetylase Isoforms
Thangapandian, S., John, S., Lee, Y., Arulalapperumal, V., & Lee, K. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049327 · Cited by 30
Mazumder, A., Vesole, D. H., & Jagannath, S. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.022 · Cited by 30
Sholler, G. L. S., Currier, E. A., Dutta, A., Slavik, M. A., Illenye, S., Mendonça, M. C., Dragon, J. A., Roberts, S. S., & Bond, J. P. (2013) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-2-21 · Cited by 29
Discovery and Mechanism of Natural Products as Modulators of Histone Acetylation
Salvador, L. A., & Luesch, H. (2012) · Current Drug Targets · doi:10.2174/138945012802008973 · Cited by 29
Dimicoli, S., Jabbour, E. J., Borthakur, G. M., Kadia, T. M., Estrov, Z. E., Yang, H., Kelly, M. A., Pierce, S. A., Kantarjian, H. M., & Garcia‐Manero, G. (2011) · American Journal of Hematology · doi:10.1002/ajh.22198 · Cited by 29
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth
Weinlander, E. J., Somnay, Y. R., Harrison, A. D., Wang, C., Cheng, Y., Jaskula‐Sztul, R., Yu, X.-M., & Chen, H. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.02.042 · Cited by 29
Ganai, S. A., Shanmugam, K., & Mahadevan, V. (2014) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2013.879073 · Cited by 27
Identification of KD5170: A novel mercaptoketone-based histone deacetylase inhibitor
Payne, J. E., Bonnefous, C., Hassig, C. A., Symons, K. T., Guo, X., Nguyen, P.-M., Annable, T., Wash, P. L., Hoffman, T. Z., Rao, T. S., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.029 · Cited by 27
Thangapandian, S., John, S., & Lee, K. W. (2012) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2012.10507409 · Cited by 27
Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors
Taddei, M., Cini, E., Giannotti, L., Giannini, G., Battistuzzi, G., Vignola, D., Vesci, L., & Cabri, W. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.072 · Cited by 24
Ma, T., Galimberti, F., Erkmen, C. P., Memoli, V. A., Chinyengetere, F., Sempere, L. F., Beumer, J. H., Anyang, B. N., Nugent, W. C., Johnstone, D. W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0933 · Cited by 23
Discovery of Potent HDAC Inhibitors Based on Chlamydocin with Inhibitory Effects on Cell Migration
Wang, S., Li, X., Wei, Y., Xiu, Z., & Nishino, N. (2013) · ChemMedChem · doi:10.1002/cmdc.201300372 · Cited by 20
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors
Hao, C.-L., Liu, P., Zhao, L., Zhu, C., Tian, X., Wang, L., & Zhang, Z. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46135 · Cited by 20
Discovery of a novel histone deacetylase 8 inhibitor by virtual screening
Zhang, L. J., Li, M., Feng, J., Fang, H., & Xu, W. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9519-7 · Cited by 19
Platzbecker, U., Al‐Ali, H. K., Gattermann, N., Haase, D. T., Janzen, V., Krauter, J., Götze, K. S. S., Schlenk, R. F., Nolte, F., Letsch, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.325 · Cited by 18
Ligand release mechanisms and channels in histone deacetylases
Kalyaanamoorthy, S., & Chen, Y. P. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23390 · Cited by 15
Lu, H., Chen, Y., Yang, B., & You, Q. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.10.002 · Cited by 14
Yang, J.-S., Chun, T.-G., Nam, K.-Y., Kim, H.-M., & Han, G. (2012) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2012.33.6.2063 · Cited by 10
Walewski, J. A., Paszkiewicz‐Kozik, E., Borsaru, G., Moicean, A. D., Warszewska, A., Strobel, K., Biggi, A., Hauns, B., Mais, A., Henning, S. W., et al. (2010) · Blood · doi:10.1182/blood.v116.21.2811.2811 · Cited by 9
Cited by
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D. C., Rezai, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 420
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Metadata
- Authors
- Mottamal, M., Zheng, S., Huang, T., & Wang, G.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-03-02
- Volume
- 20
- Issue
- 3
- Pages
- 3898-3941
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2092476693
- Cited by
- 680
- References
- 196
- FWCI
- 37.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.